Clinical trials for prostate cancer

50 currently recruiting clinical trials
Prostate cancer

Phase 2 Prostate cancer
#NCT05489211
Metastatic Castration-resistant
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
Centre Hospitalier​ Universitaire de Bordeaux (Bordeaux), Centre Léon Bérard (Lyon), Hôpital Foch (Suresnes)
AstraZeneca
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer
#NCT05118789
SCLC (Small Cell Lung Cancer) Mesothelium Locally Advanced Metastatic Metastatic Castration-resistant ROS-1 Other mutation
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Centre Hospitalier Universitaire - Site Hôtel Dieu (Nantes), Centre Hospitalier Universitaire de Toulouse (Toulouse)
Nuvalent Inc.
Phase 2 Prostate cancer
#NCT03438552
Adenocarcinoma Biochemical recurrence Radiotherapy
Systemic Treatment-Naive Immunotherapy Chemotherapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre François Baclesse (Caen ), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre Jean Perrin (Clermont Ferrand ), Institut du cancer de Montpellier (Montpellier), Centre Oscar Lambret (Lille) (and 6 more...)
UNICANCER
Phase 2 Prostate cancer
#NCT02628067
Immunotherapy Systemic Treatment-Naive Immunotherapy
Gustave Roussy (Villejuif)
Merck Sharp & Dohme LLC
Phase 2 Prostate cancer
#NCT04585750
Metastatic Castration-resistant
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux) (and 2 more...)
PMV Pharmaceuticals, Inc
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer
#NCT05751798
MSI/dMMR PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Systemic Treatment-Naive Immunotherapy Systemic Treatment-Naive Immunotherapy
Centre Léon Bérard (Lyon)
OSE Immunotherapeutics
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer
#NCT05384626
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation
BRAF MET HER2 RET NTRK-1/2/3 KRAS G12C KRAS non G12C BRCA 1/2 AKT PIK3CA PALB2 ESR FGFR PTEN MSI/dMMR ATM CDK12 HOXB13 CHEK 1/2 NRAS Systemic Treatment-Naive
Gustave Roussy (Villejuif), IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Nuvalent Inc.
Phase 2 Prostate cancer
#NCT03845751
Localized Systemic Treatment-Naive
Institut Mutualiste Montsouris (Paris)
Institut Mutualiste Montsouris
Phase 2 Prostate cancer
#NCT05346848
Localized Systemic Treatment-Naive
Chemotherapy Hormone therapy Radiotherapy Internal Vectorised Radiotherapy (IVR) Surgery
Institut Bergonié (Bordeaux)
Institut Bergonié
Phase 2 Prostate cancer
#NCT04536805
Biochemical recurrence Radiotherapy Surgery Hormone therapy
Centre Hospitalier Régional Et Universitaire CHRU de Brest (Brest), Centre Oscar Lambret (Lille), Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire Laennec (Saint-Herblain), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ) (and 1 more...)
Institut de Cancérologie de l'Ouest